Is Takeda's Upgraded FY2025 Outlook And New PID Therapy Altering The Investment Case For Takeda (TSE:4502)? [Yahoo! Finance]
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) (TAK)
Company Research
Source: Yahoo! Finance
billions, alongside slightly higher earnings per share year-on-year, and raised its full-year 2025 revenue and profit guidance. Takeda also announced U.S. availability of GAMMAGARD LIQUID ERC for primary immunodeficiency, adding a ready-to-use immunoglobulin therapy that could broaden its rare disease treatment offering. Next, we'll examine how Takeda's upgraded full-year guidance reshapes its investment narrative in light of these recent product and earnings developments. We've found 12 US stocks that are forecast to pay a dividend yield of over 6% next year . See the full list for free. For Takeda, the big picture an investor needs to believe in is a large, diversified pharma group that can use its pipeline and specialty focus to offset patent losses and still grow earnings over time. The latest nine-month FY2025 results and slightly higher EPS show resilience despite softer revenue, and the guidance upgrade, while modest, helps repair some confidence after last year's downg
Show less
Read more
Impact Snapshot
Event Time:
TAK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TAK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TAK alerts
High impacting Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) news events
Weekly update
A roundup of the hottest topics
TAK
News
- Takeda Pharmaceutical (TSE:4502) Valuation Check After Recent Share Price Momentum And Mixed Fair Value Signals [Yahoo! Finance]Yahoo! Finance
- Is Takeda Pharmaceutical Company Limited (TAK) One of the Best Healthcare Stocks to Buy for 2026? [Yahoo! Finance]Yahoo! Finance
- Takeda Pharmaceutical (NYSE:TAK) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=TAK&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street MarketBeat
- Takeda Tests New Highs, But Struggles To Find Entyvio Successor [Seeking Alpha]Seeking Alpha
- Takeda Reports Third-Quarter FY2025 Results: Updates Full Year Outlook to Reflect VYVANSE® Generics Impact, OPEX Discipline and FX Tailwind; Progressing Toward Three Transformative Launches AheadBusiness Wire
TAK
Sec Filings
- 1/29/26 - Form 6-K
- 12/18/25 - Form 6-K
- 12/9/25 - Form 144
- TAK's page on the SEC website